Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Sildenafil and Cardioprotection

Author(s): Rakesh C. Kukreja

Volume 19, Issue 39, 2013

Page: [6842 - 6847] Pages: 6

DOI: 10.2174/138161281939131127110156

Price: $65

Abstract

The phosphodiesterese-5 (PDE5) inhibitors, including sildenafil (Viagra™), vardenafil (Levitra™), tadalafil (Cialis™) and avanafil (Stendra™) have been developed for the treatment of erectile dysfunction. Moreover, sildenafil and tadalafil have been approved for the management of pulmonary arterial hypertension. A number of preclinical studies have shown that PDE5 inhibitors have powerful protective effect against several clinical scenarios including myocardial ischemia/reperfusion injury, doxorubicin and post-MI, heart failure, cardiac hypertrophy, heart transplantation, Duchenne muscular dystrophy and preconditioning of stem cells. Based on these studies, it appears that sildenafil and other PDE5 inhibitors hold promise for further development as novel drug therapies in cardioprotection.

Keywords: Ischemia, heart-failure, cardioprotection, phosphodiesterase-s, cGMP.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy